Key result
Triple therapy with aspirin, clopidogrel, and rivaroxaban followed by dual therapy resulted in LV thrombi resolution at 12 months with no thromboembolic episodes.
Case Report (n=1)
Short-term triple therapy with rivaroxaban 15 mg/day followed by dual therapy successfully resolved LV thrombus without thromboembolic complications in a complex AF patient post-PCI.
We present the complex case of a high-risk patient with nonvalvular atrial fibrillation, who experienced a non-ST elevation myocardial infarction complicated by left ventricular (LV) thrombi and underwent percutaneous coronary intervention with drug-eluting stent implantation. The patient was initially treated with short-term triple therapy including aspirin, clopidogrel, and rivaroxaban 15 mg/die. Following aspirin dropping one month after discharge, the patient continued on dual therapy with clopidogrel and rivaroxaban, and a clinical and imaging follow-up at 6 and 12 months confirmed the LV thrombi resolution, with no thromboembolic episodes and a good safety profile.
No takes yet. Share an insight, caveat, or question.
Summaria et al. (2018) conducted a case report in Nonvalvular atrial fibrillation, NSTEMI, left ventricular thrombi (n=1). Triple therapy (aspirin, clopidogrel, rivaroxaban) followed by dual therapy was evaluated on LV thrombi resolution and thromboembolic episodes. Triple therapy with aspirin, clopidogrel, and rivaroxaban followed by dual therapy resulted in LV thrombi resolution at 12 months with no thromboembolic episodes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: